



Amaxa® HMEC Nucleofector® Kit

For Human Mammary Epithelial Cells (HMEC)


Validated to work with Clonetics® HMEC [Lonza; Cat. No. CC-2551]; adherent epithelial cells

Example for Nucleofection® of HMECs





HMECs were transfected with the HMEC Nucleofector® Kit, program Y-001 using a plasmid encoding the green fluorescent protein, maxGFP® Vector. 24 hours post Nucleofection® the cells were analyzed by light (A) or fluorescence microscopy (B).



Transfection efficiency of HMECs 24 hours post Nucleofection®. Cells were transfected with program W-001 or Y-001 and 2 μg of pmaxGFP® Vector. 24 hours post Nucleofection® cells were analyzed by flow cytometry.

Product Description

Cat. No.	VPK-1002
Size (reactions)	25
Human Mammary Epithelial Cell (HMEC) Nucleofector® Solution	2.25 ml (2.05 ml + 10% overfill)
Supplement	0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 μg/μl in 10 mM Tris pH 8.0)	30 µg
Certified cuvettes	25
Plastic pipettes	25

Storage and stability

Store Nucleofector® Solution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage, pmaxGFP® Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution it is stable for three months at 4°C.

Optimized Protocol for Human Mammary Epithelial Cells (HMEC)

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector® Solution. The ratio of Nucleofector® Solution to supplement is 4.5:1. For a single reaction use $82\,\mu$ l of Nucleofector® Solution plus $18\,\mu$ l of supplement to make $100\,\mu$ l of total reaction volume.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260:A280 ratio should be at least 1.8
- 6-well culture dish or culture system of your choice
- For trypsinization: Reagent Pack™ Subculture Reagent Kit containing Trypsin/EDTA, HEPES Buffered Saline Solution (HBSS) and Trypsin Neutralizing Solution (TNS) [Lonza, Cat. No. CC-5034]
- Culture medium: MEGM® BulletKit® [Lonza; Cat. No. CC-3150]. Use 30 ml per 162 cm² flask (2 day culture), 40 ml per 162 cm² flask (3 day culture). We recommend storing 40 ml aliquots of the prepared medium at -80°C. Do not use medium stored at 4°C for more than two days, as this may lead to reduced cell viability and transfection efficiency.
- Prewarm appropriate volume of culture media at 37°C (1.5 ml per reaction)
- Appropriate number of cells (0.5 x 10^6 cells per sample); for lower cell numbers we recommend using program W-001; minimal cell number: 5×10^4 cells (viability might decrease); maximal cell number: 1×10^6 cells

1. Pre Nucleofection®

Note

Transfection results may be donor - dependent.

Cell culture recommendations

- 1.1 Seeding conditions: 2500 cells/cm². Use flasks with a surface area of 75 cm² only. High cell densities in HMEC culture lead to increased cell mortality and reduced transfection efficiency. This could not be compensated by low density culturing afterwards
- 1.2 Replace media every 2 3 days
- 1.3 Cells should be passaged every 2 3 days
- 1.4 For Nucleofection $^{\circ}$ cells should be preferably passaged 2 3 days before
- 1.5 Do not use cells after passage number 14 as this may result in substantially lower gene transfer efficiency and viability
- 1.6 Optimal confluency before Nucleofection®: 40%

Trypsinization

- 1.7 Remove media from the cultured cells and wash cells once with HBSS; use at least same volume of HBSS as culture media
- 1.8 For harvesting, incubate the cells ~5 minutes at 37°C with recommended volume of indicated trypsinization reagent (please see required material)
- 1.9 Neutralize trypsinization reaction with TNS once the majority of the cells (>90%) have been detached (latest after 7 minutes as otherwise cells may start to clump)

Optimized Protocol for Human Mammary Epithelial Cells (HMEC)

2. Nucleofection®

One Nucleofection® Sample contains

 0.5×10^6 cells

 $0.5-5~\mu g$ plasmid DNA (in $1-5~\mu l$ H $_20$ or TE) or $2~\mu g$ pmaxGFP® Vector or 30-300~n M siRNA (3-30~pmol/sample)

100 µI HMEC Nucleofector® Solution

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 6-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified $37^{\circ}\text{C/}5\%$ CO₂ incubator
- 2.3 Harvest the cells by trypsinization (please see 1.7 1.9)
- 2.4 Count an aliquot of the trypsinized cells and determine cell density
- 2.5 Centrifuge the required number of cells $(0.5 \times 10^6 \text{ cells per sample})$ at 200xg for 6 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector® Solution per sample
- 2.7 Combine 100 μ l of cell suspension with 0.5 5 μ g DNA, 2 μ g pmaxGFP® Vector or 30 nM 300 nM siRNA (3 30 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.9 Select the appropriate Nucleofector® Program W-001 for high viability or Y-001 for high transfection efficiency (W-01 or Y-01 for Nucleofector® | Device)
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Add \sim 500 μ l of the pre-equilibrated culture media to the cuvette and gently transfer the sample immediately into the 6-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection®

3.1 Incubate the cells in a humidified 37° C/5% CO₂ incubator until analysis. Gene expression is often detectable after only 4 – 8 hours

Optimized Protocol for Human Mammary Epithelial Cells (HMEC)

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA/Canada Europe and Rest of World

Phone: 800 521 0390 (toll-free) Phone: +49 221 99199 400

Fax: 301 845 8338 Fax: +49 221 99199 499

Lonza Cologne AG 50829 Cologne, Germany

 $Please \ note that \ the \ Amaxa^{@}\ Nucleofector^{@}\ Technology\ is\ not\ intended\ to\ be\ used\ for\ diagnostic\ purposes\ or\ for\ testing\ or\ treatment\ in\ humans.$

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection, maxGFP, Reagent Pack, MEGM and BulletKit are either registered trademarks or trademarks of the Lonza Group or its affiliates.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

@ Copyright 2009, Lonza Cologne AG. All rights reserved DPK-1002 08/09